Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Capital Expenditures (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Capital Expenditures for 11 consecutive years, with -$91.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 121.81% to -$91.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.3 million through Dec 2025, down 84.33% year-over-year, with the annual reading at $57.3 million for FY2025, 88.37% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$91.0 million at BeOne Medicines, down from $90.4 million in the prior quarter.
  • The five-year high for Capital Expenditures was $454.3 million in Q4 2023, with the low at -$91.0 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $78.7 million, with a median of $21.5 million recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 651.83% in 2021, while the deepest fall reached 629.57% in 2021.
  • Over 5 years, Capital Expenditures stood at $221.0 million in 2021, then rose by 25.82% to $278.1 million in 2022, then soared by 63.34% to $454.3 million in 2023, then decreased by 8.13% to $417.3 million in 2024, then plummeted by 121.81% to -$91.0 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$91.0 million, $90.4 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.